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Abstract
We describe a 66-year-old woman hospitalized with fever,
fatigue and hepatopathy. In her medical history arterial
hypertension (treated with propranolol and lisinopril), diabetes
mellitus type 2 (no treatment before admission) and a gout
arthropathy were noted wherefore a therapy with allopurinol
300 mg per day has been started 4 months before. Liver biopsy
revealed fibrin-ring granulomas, compatible with allopurinol-
induced hepatitis. Because of persistence of high fever after
stopping allopurinol, steroids (1 mg/kg) were started. Under
this treatment, she developed pancytopenia and fever. The bone
marrow aspiration revealed Leishmania infantum. A second liver
biopsy showed amastigotes and a disappearance of the
granulomas. The history revealed a travel to Malta 2 years
earlier. Despite adequate treatment with liposomal amphoter-
icin B the patient deteriorated and finally died in septic shock.
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Introduction
Fibrin-ring granulomas in liver biopsy specimens of acute
hepatitis are a rare and unspecific finding. Possible causes
include Morbus Hodgkin, drug reactions, rheumatic dis-
eases and infections. Pathogens associated with fibrin-ring
granulomas are Coxiella burnetii, Mycobacterium tuber-
culosis and Leishmania spp. Leishmaniasis can be reacti-
vated in immunocompromised patients years after
primary infection. Typical clinical symptoms may then be
absent, leading to a delay in diagnosis and more severe
course of infection. Due to human migration and in-
creased tourism, visceral leishmaniasis may become more
common in non-endemic areas.
Case
A 66-year-old woman was referred for progressive weakness,
fatigue, fever and dizziness over the last 3 weeks. In the medical
history arterial hypertension, diabetes mellitus type 2 and a gout
arthropathy were noted. Medication consisted of lisinopril 5 mg,
propranolol 40 mg and allopurinol 300 mg daily started 4 months
ago.
At admission the patient was in a reduced condition and
febrile (38 C). The physical examination revealed adipositas
(BMI 31 kg/m2), edema of the lower extremities and spleno-
megaly. Blood tests showed elevated liver enzymes (ASAT
202 U/l [11–36 U/l], ALAT 89 U/l [10–37 U/l], bilirubin
19.7 lmol/l [5–18 lmol/l], gGT 243 U/l [8–49 U/l] and alkaline
phosphatase 236 U/l [31–108 U/l]). The platelet count was low
(72 · 109/l), the absolute number of leukocytes was normal with
shift to band forms (25%). An abdominal ultrasound showed
hyperechogenity of the liver and a splenomegaly of 14 · 6 cm.
Serologic tests for HBV, HAV and HCV were negative.
A liver biopsy revealed an extensive granulomatous hepa-
titis with fibrin-ring granulomas (Figure 1a, b). Possible etiolo-
gies of fibrin-ring granulomas as infections with Coxiella burnetii,
Rickettsia spp., Leptospira spp., Salmonella spp., CMV and HIV
were excluded by serologies and/or cultures. M. tuberculosis was
not found in the liver biopsy (Ziehl-Neelsen, PCR and cultures).
Antimitochondrial antibodies, antineutrophil cytoplasmic anti-
bodies and antinuclear antibodies were negative. A bone marrow
biopsy and a computer tomography did not show signs of lym-
phoma. Neither in the biopsy of the liver nor that of the bone
marrow were amastigotes detected. Finally, the granulomatous
hepatitis was interpreted as allopurinol-associated and allopuri-
nol was stopped. Because of the persisting high fever and dis-
comfort of the patient a treatment with prednisone 75 mg per
day was started and the dosage was slowly tapered. The patient’s
condition improved and she was discharged.
After 3 weeks of therapy with a total of 1,050 mg predni-
sone, the patient was readmitted with pancytopenia (platelets
20 · 109 per liter, hemoglobin 110 g/l, leukocytes 0.97 · 109 per
liter, neutrophils 0.56 · 109 per liter) and persistently elevated
liver enzymes (ASAT 104 U/l, ALAT 91 U/l, gGT 1,188 U/l,
alkaline phosphatase 305 U/l, bilirubin 68 lmol/l). The liver and
bone marrow biopsies were repeated. Now an extensive infil-
tration with amastigotes was seen in the liver (Figure 2) and
bone marrow (Figure 3), identified as Leishmania infantum by
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polymerase chain reaction (restriction fragment length poly-
morphism, PCR-RFLP [1]) in blood and liver biopsy. Also the
serology (immunofluorescence test) for leishmania infantum was
strongly positive. There was no evidence of fibrinous granulomas
anymore in the liver biopsy. The travel history revealed a vaca-
tion in the Mediterranean island of Malta 2 years before. A
therapy with liposomal amphotericin B 3 mg/kg was started and
well tolerated. After 8 days of therapy the patient developed
pneumonia with Pneumocystis jiroveci and multiorgan failure
and she died 23 days after initiation of antiparasitic treatment.
The autopsy showed only a discrete persistent infiltration of
amastigotes in the liver and bone marrow. Retrospectively the
initial bone marrow and liver biopsies were reexamined by an
experienced pathologist. No amastigotes were found in those
specimens. The PCR analysis was not repeated in the biopsies.
Discussion and Conclusion
The differential diagnosis of granulomatous hepatitis is
broad. Sarcoidosis, tuberculosis, primary biliary cirrhosis
and drug-induced hepatitis are the most common etiolo-
gies. Fibrin-ring granulomas are rare and can be due to
infections with C. burnetii, EBV, CMV, Hepatitis A or
Leishmania spp., Morbus Hodgkin and drug toxicity from
allopurinol [2]. In our case infectious etiologies were not
found by serology and cultures, the liver and bone marrow
biopsies were negative for amastigotes and there was no
evidence of lymphoma in the abdominal CT scan.
After exclusion of infectious and malignant causes,
the diagnosis of allopurinol-induced hepatitis was made,
although the clinical presentation with edema and
splenomegaly was not typical and features of an allergic
drug reaction like rash, arthralgias and eosinophilia were
lacking.
In the allopurinol-associated hypersensitivity syn-
drome, clinical symptoms are evident most often 4–6 weeks
after initiation of therapy, including fever, rash, arthralgias
and eosinophilia. Usually the patients recover within
6 weeks after cessation of allopurinol [3]. Our patient was
hospitalized because of fever and hepatopathy 4 months
after starting allopurinol.
Besides heterogeneous clinical manifestations,
Leishmania infections can remain asymptomatic, espe-
cially in immunocompetent patients [4], whereas, severe
disease is possible despite low parasite load. The liver
involvement in visceral leishmaniasis may appear as
chronic granulomatous hepatitis [5]. Fulminant hepatitis
has been described in 3 of 150 immunocompetent children
with Kala-azar in an Indian study [6].
Visceral leishmaniasis is usually diagnosed in bone
marrow, spleen, lymph nodes and liver biopsy [7–9]. The
bone marrow and liver biopsies in our patient were ini-
tially negative for Leishmania. Retrospectively, it is not
Figure 2. Several parasites are present in Kupffer cells and in some
hepatocytes (amastigote form of Leishmania) (H.E. ·400).
Figure 1. (a) Liver parenchyma showing
preserved lobular architecture, macro-
vesicular steatosis and diffuse granuloma-
tous hepatitis with several fibrin-ring
granulomas (H.E. ·100). (b) The granulomas
display a central fatty vacuole and the
surrounding macrophages are trapped in a
mesh of fibrin (H.E. ·400).
Figure 3. Bone marrow biopsy showing numerous Leishmania
(Giemsa, ·630).
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clear whether the initial finding of fibrin-ring granulomas
was due to occult visceral leishmaniasis or to allopurinol
therapy. Interestingly, allopurinol is used in combination
with antimoniate for the treatment of cutaneous leish-
maniasis [10], while in visceral leishmaniasis the results of
this combination therapy are not so promising, either
because of relapses [11] or of lacking effectiveness [12]. In
combination with ketoconazole, allopurinol was reported
to be successful for visceral leishmaniasis in renal trans-
plantation although in a higher dose than that used in the
treatment of gout arthropathy (600 mg vs. 300 mg) [13].
One could hypothesize therefore, that allopurinol led to a
disappearance of the parasites, while the granulomatous
hepatitis persisted. Furthermore, in the natural course of
leishmaniasis, formation of granulomas is a sign of strong
cellular immune response with few parasites found in
examined tissue and an a- to oligo-symptomatic state of
disease.
After stopping the treatment and starting an immu-
nosuppressive therapy with prednisone, a progression to
fulminant leishmaniasis occurred, and the liver granulomas
disappeared. Steroids, alone or in combination with other
immunosuppressive medications, are a known risk factor
for severe courses of infection with Leishmania [14, 15].
Our patient must have acquired the infection two
years before the start of symptoms on a vacation in Malta,
where L. infantum is endemic. Prolonged latent infection
with the appearance of symptoms only after immuno-
suppression was started has been described [16, 17].
In conclusion, like other emerging infectious diseases
visceral leishmaniasis becomes more common in non-en-
demic regions with migration and tourism. Therefore, a
travel history is mandatory in all patients. In patients with
alterated immune status (e.g., disease or therapy-associ-
ated) and granulomatous hepatitis, leishmaniasis has to be
strongly considered and searched repeatedly. In patients
with fever, hepatosplenomegaly and pancytopenia with a
travel history to endemic areas, serology for Leishmania
spp. is a useful screening test.
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